Videos
Richard Lewis, MD, founder of Sacramento Eye Consultants, says the arrival of MIGS has completely changed how physicians can treat glaucoma. In this interview, Lewis…
Read MoreJerry St. Peter, VP & head, ophthalmic business, says the ophthalmology newcomer is making great progress in building broad pipeline to treat eye disease including…
Read MoreFrederic Guerard, worldwide business franchise head, ophthalmology, explains how the pharmaceutical giant came to make large bets in presbyopia and dry eye. “I’d like to…
Read MoreLaurent Attias, head, strategy, BD&L and M&A, updates OIS-TV on the progress of Cypass, Alcon’s big bet in glaucoma. He also updates on the company’s…
Read MoreElizabeth Yeu, MD, of Virginia Eye Consultants, updates OIS-TV on advances in presbyopia and dry eye that impact patients the most. She also reveals the…
Read MoreTom Frinzi, worldwide president, surgical, Johnson & Johnson Vision, says the cultural fit of Johnson & Johnson and Abbott Medical Optics helped ease the merger…
Read MoreEric Donnenfeld, MD, founding partner of OCLI, shares how his practice is incorporating new diagnostics and treatments. “I spend less time diagnosing the disease and…
Read MorePerry Sternberg, head of US commercial at Shire, updates OIS-TV on the progress of Shire’s dry eye blockbuster, Xiidra, and its growing ophthalmic pipeline. He…
Read MoreIn this interview, Tom Mitro, COO of Aerie Pharmaceuticals, says the new hires brought on to prepare for commercial sale of Rhopressa bring new life…
Read MoreLudwin Monz, PhD, president and CEO of Carl Zeiss Meditec, explains why the ophthalmology leader brought in new senior leadership. He also reviews the company’s…
Read MoreAlice Epitropoulos, MD, of Ophthalmic Surgeons & Consultants of Ohio, sat down with OIS-TV to explain how Shire, TrueTear and other advances are impacting her…
Read MoreMichael Lachman, president of EyeQ Research, delivers an update regarding the OIS Index. Given some of the disappointing clinical news in recent months, it’s no…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.